Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in LEPR Deficiency Obesity
NCT03287960Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Sep 2020
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of setmelanotide in Leptin Receptor Deficiency, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Percentage of Participants Who Reached >=10% Weight Loss Threshold After 1 Year. Started Jan 2018; status: completed.
02
Drugs
setmelanotide
03
Conditions
Leptin Receptor Deficiency
Beyond the preview
Go deeper on NCT03287960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287960.